These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32421451)

  • 21. Signaling cross-talk in the resistance to HER family receptor targeted therapy.
    Yamaguchi H; Chang SS; Hsu JL; Hung MC
    Oncogene; 2014 Feb; 33(9):1073-81. PubMed ID: 23542173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [MET receptor inhibition: Hope against resistance to targeted therapies?].
    Hochart A; Leblond P; Le Bourhis X; Meignan S; Tulasne D
    Bull Cancer; 2017 Feb; 104(2):157-166. PubMed ID: 27863726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of targeted therapy for gastrointestinal tumors.
    Rolfo C; Bronte G; Sortino G; Papadimitriou K; Passiglia F; Fiorentino E; Marogy G; Russo A; Peeters M
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):875-85. PubMed ID: 24957206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapy for metastatic colorectal cancer.
    Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All.
    Martins M; Mansinho A; Cruz-Duarte R; Martins SL; Costa L
    Adv Exp Med Biol; 2018; 1110():113-131. PubMed ID: 30623369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Esophagogastric cancer: integration of targeted therapies into systemic chemotherapy.
    Moehler M; Schwarz S; Wagner AD
    Curr Cancer Drug Targets; 2011 Jul; 11(6):681-7. PubMed ID: 21651462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
    Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer.
    Bregni G; Sciallero S; Sobrero A
    JAMA Oncol; 2019 May; 5(5):605-606. PubMed ID: 30869746
    [No Abstract]   [Full Text] [Related]  

  • 30. Resistance to Anti-HER2 Therapies in Breast Cancer.
    Rimawi MF; De Angelis C; Schiff R
    Am Soc Clin Oncol Educ Book; 2015; ():e157-64. PubMed ID: 25993167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
    Efferth T
    Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
    Grygielewicz P; Dymek B; Bujak A; Gunerka P; Stanczak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K; Zdzalik D
    Gastric Cancer; 2016 Jan; 19(1):53-62. PubMed ID: 25407459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
    Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
    Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy.
    Takegawa N; Yonesaka K
    Clin Colorectal Cancer; 2017 Dec; 16(4):247-251. PubMed ID: 28363756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Perspectives of the stomach cancer treatment: the introduction of molecular targeted therapy and the hope for cure].
    Cheung DY; Kim JK
    Korean J Gastroenterol; 2013 Mar; 61(3):117-27. PubMed ID: 23575230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical update on K-Ras targeted therapy in gastrointestinal cancers.
    Pant S; Hubbard J; Martinelli E; Bekaii-Saab T
    Crit Rev Oncol Hematol; 2018 Oct; 130():78-91. PubMed ID: 30196915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The drug treatment research of gastrointestinal cancer in China.
    Ren C; Xu RH
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e3-e6. PubMed ID: 32591201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
    Huang Y; Fu P; Fan W
    Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tumor resistance to HER2 inhibitors: the drug sedimentation concept].
    Campone M; Frenel JS; André F; Bachelot T; Juin P
    Bull Cancer; 2012 Jun; 99(6):665-72. PubMed ID: 22614782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.